In recent years, we have witnessed tremendous progress in both the diagnosis and treatment of haematological malignancies in children. The development the modern molecular methods allowed the identification of numerous unique expression profiles of haematological malignancies. Advances in understanding the molecular biology of cancer disease, genetic predispositions to haematological cancers, and the mechanism of drug resistance guide novel therapy strategies, called precision treatment.
The field of precision medicine has exploded through progress in sequencing technologies. Identifying genetic abnormalities is critical to achieving better outcomes in pediatric malignancies, but the development of drugs that block specific proteins and pathways remains challenging.
We invite submissions of both review papers and original research articles on topics covering the use of novel therapies in hematological malignancies.
In recent years, we have witnessed tremendous progress in both the diagnosis and treatment of haematological malignancies in children. The development the modern molecular methods allowed the identification of numerous unique expression profiles of haematological malignancies. Advances in understanding the molecular biology of cancer disease, genetic predispositions to haematological cancers, and the mechanism of drug resistance guide novel therapy strategies, called precision treatment.
The field of precision medicine has exploded through progress in sequencing technologies. Identifying genetic abnormalities is critical to achieving better outcomes in pediatric malignancies, but the development of drugs that block specific proteins and pathways remains challenging.
We invite submissions of both review papers and original research articles on topics covering the use of novel therapies in hematological malignancies.
